# US 2026/0295957 A1 · Methods, agents, and devices for local neuromodulation of autonomic nerves

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0295957 A1
- Document ID: US20260295957A1
- Status: Published application
- Kind: A1
- Application number: 19/677,836
- Filed: 2026-05-14
- Published: 2026-10-01
- Earliest claimed: 2016-02-09
- Assignees: Tulavi Therapeutics, Inc.
- Applicants: Tulavi Therapeutics, Inc.
- Inventors: Corinne Bright; Kondapavulur T. Venkateswara-Rao; Emily Stein
- Web page: https://patentgrep.com/patent/US20260295957A1

## CPC

- B29C 73/10: using patches sealing on the surface of the article (B29C73/14 takes precedence)
- B29C 73/34: for local heating
- B29C 2073/262: {for polishing, roughening, buffing or sanding the area to be repaired}
- B29C 2793/0027: Cutting off
- B29L 2031/3076: {Aircrafts (blades, propellers B29L2031/08)}
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B29L: INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES

## Abstract

Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

## Claims

### Claim 1

A system to treat angina, the system comprising:
a syringe; and
a composition housed within the syringe, the composition comprising:
a hydrogel, and
an agent comprising a dihydropyridine calcium antagonist,
wherein the composition is configured to be delivered locally to a stellate ganglion of a patient in an amount sufficient to affect function of the stellate ganglion and alleviate one or more symptoms of angina in the patient.

### Claim 2 (depends on 1)

The system of claim 1, wherein the dihydropyridine calcium antagonist comprises amlodipine.

### Claim 3 (depends on 1)

The system of claim 1, wherein the dihydropyridine calcium antagonist comprises nifedipine.

### Claim 4 (depends on 1)

The system of claim 1, wherein the agent further comprises non-dihydropyridine calcium antagonists.

### Claim 5 (depends on 1)

The system of claim 1, wherein the agent further comprises a beta blocker.
